Table 3.

Pharmacokinetic parameter values for each genotype group calculated with population pharmacokinetic predictions of 5th−5%, 5th−50%, 5th−95%, 50th−5%, 50th−50%, 50th−95%, 95th−5%, 95th−50%, and 95th−95% (percentage of total population−percentage in range), as a result of the fexofenadine population pharmacokinetic model visual predictive check established by considering the organic-anion-transporting-polypeptide 2B1 (OATP2B1) genetic polymorphism as a covariate (following single oral exposure to 180 mg of fexofenadine). The 5th, 50th, and 95th mean 5th, 50th, and 95th percentiles of the predicted concentrations for each group; the 5%, 50%, and 95% mean 5%, 50%, and 95% confidence interval (CI) ranges in each percentile.

Parameters	SLCO2B1 1457C > T genotypes
	CC	CT/TT
t1/2 (h)	2.92 ± 0.13	3.38 ± 0.14∗
tmax (h)	1.72 ± 0.26	1.83 ± 0.25
cmax (ng/mL)	930.28 ± 474.74	503.06 ± 283.14∗
AUC0−t (h·ng/mL)	5110.29 ± 2500.48	2984.28 ± 1615.63∗
AUC0−∞ (h·ng/mL)	5617.20 ± 2708.82	3408.37 ± 1807.09∗
V/F (L)	166.90 ± 88.34	334.45 ± 197.19∗
CL/F (L/h)	38.89 ± 18.44	67.35 ± 36.20∗
MRT (h)	5.13 ± 0.20	5.82 ± 0.27∗
R value a	1.06 ± 0.01	1.09 ± 0.01∗

^aR value meant the accumulation ratio and was calculated by the following formula: $\frac{1}{1-e^{-k\times \tau }}$ In the formula, k and τ represent the elimination rate constant of fexofenadine and the dosing interval (as 12 h) for multiple exposures, respectively.

^∗P < 0.05 between SLCO2B1 1457CC and CT/TT groups. T: thymine; C: cytosine; t_1/2: half-life; c_max: peak plasma concentration; t_max: time to reach c_max; AUC: area under the time-plasma concentration curve; V/F: volume of distribution; CL/F: clearance; MRT: mean residence time.